EUVIMEDObjevte EUVIMED
Open access

Large library docking for novel SARS‐CoV ‐2 main protease non‐covalent and covalent inhibitors

Elissa A Fink, Conner Bardine, Stefan Gahbauer, Isha Singh, Tyler C Detomasi, Kris White, Shuo Gu, Xiaobo Wan, Jun Chen, Beatrice Ary, Isabella Glenn, Joseph O'Connell and 19 more

Protein Science · 2023

DOI: 10.1002/pro.4712 ↗

At a glance

Journal article in Protein Science, 2023. Written by Elissa A Fink and 30 co-authors. Institution: Department of Pharmaceutical Chemistry, University of California-San Francisco, San Francisco, California, USA. Major MEDLINE topics: COVID-19. Cited 32 times so far (Crossref); 108 references. The full text is freely available in PubMed Central. Funded by: NIH HHS, NIGMS NIH HHS, NIAID NIH HHS.

AbstraktSubjectsBibliografické údajeCiteRelated studies

Abstract (original language)

Antiviral therapeutics to treat SARS‐CoV‐2 are needed to diminish the morbidity of the ongoing COVID‐19 pandemic. A well‐precedented drug target is the main viral protease (M Pro ), which is targeted by an approved drug and by several investigational drugs. Emerging viral resistance has made new inhibitor chemotypes more pressing. Adopting a structure‐based approach, we docked 1.2 billion non‐covalent lead‐like molecules and a new library of 6.5 million electrophiles against the enzyme structure. From these, 29 non‐covalent and 11 covalent inhibitors were identified in 37 series, the most potent having an IC 50 of 29 and 20 μM, respectively. Several series were optimized, resulting in low micromolar inhibitors. Subsequent crystallography confirmed the docking predicted binding modes and may template further optimization. While the new chemotypes may aid further optimization of M Pro inhibitors for SARS‐CoV‐2, the modest success rate also reveals weaknesses in our approach for challenging targets like M Pro versus other targets where it has been more successful, and versus other structure‐based techniques against M Pro itself.

Subjects

MeSH terms (MEDLINE)

COVID-19HumansSARS-CoV-2PandemicsProtease InhibitorsMolecular Docking SimulationViral Nonstructural ProteinsAntiviral AgentsCoronavirus 3C Proteases

Author keywords

SARS-COV-2discoverydockinganti-viralmajor proteasestructure-based inhibitor

Substances

Protease InhibitorsViral Nonstructural ProteinsAntiviral Agents3C-like proteinase, SARS-CoV-2Coronavirus 3C Proteases

Authors and institutions

  • Department of Pharmaceutical Chemistry, University of California-San Francisco, San Francisco, California, USA.
  • Graduate Program in Biophysics, University of California-San Francisco, San Francisco, California, USA.
  • Graduate Program in Chemistry and Chemical Biology, University of California-San Francisco, San Francisco, California, USA.
  • Department of Microbiology, Icahn School of Medicine at Mount Sinai, New York, New York, USA.
  • Global Health and Emerging Pathogens Institute, Icahn School of Medicine at Mount Sinai, New York, New York, USA.
  • Skaggs School of Pharmacy and Pharmaceutical Sciences, University of California-San Diego, San Diego, California, USA.

ORCID profiles: Brian K Shoichet

Funding

  • NIH HHS
  • NIGMS NIH HHS
  • NIAID NIH HHS
  • National Institutes of Health
  • National Institute of Allergy and Infectious Diseases
  • U.S. Department of Defense
  • Defense Advanced Research Projects Agency

Cite

APA

Fink, E. A., Bardine, C., Gahbauer, S., Singh, I., Detomasi, T. C., White, K., Gu, S., Wan, X., Chen, J., Ary, B., Glenn, I., O'Connell, J., O'Donnell, H., Fajtová, P., Lyu, J., Vigneron, S., Young, N. J., Kondratov, I. S., Alisoltani, A., …, & Craik, C. S. (2023). Large library docking for novel SARS‐CoV ‐2 main protease non‐covalent and covalent inhibitors. Protein Science. https://doi.org/10.1002/pro.4712

Vancouver

Fink EA, Bardine C, Gahbauer S, Singh I, Detomasi TC, White K, et al. Large library docking for novel SARS‐CoV ‐2 main protease non‐covalent and covalent inhibitors. Protein Science. 2023. doi:10.1002/pro.4712

BibTeX
@article{Fink2023,
  author = {Fink, Elissa A and Bardine, Conner and Gahbauer, Stefan and Singh, Isha and Detomasi, Tyler C and White, Kris and Gu, Shuo and Wan, Xiaobo and Chen, Jun and Ary, Beatrice and Glenn, Isabella and O'Connell, Joseph and O'Donnell, Henry and Fajtová, Pavla and Lyu, Jiankun and Vigneron, Seth and Young, Nicholas J and Kondratov, Ivan S and Alisoltani, Arghavan and Simons, Lacy M and Lorenzo-Redondo, Ramon and Ozer, Egon A and Hultquist, Judd F and O'Donoghue, Anthony J and Moroz, Yurii S and Taunton, Jack and Renslo, Adam R and Irwin, John J and García-Sastre, Adolfo and Shoichet, Brian K and Craik, Charles S},
  title = {Large library docking for novel SARS‐CoV ‐2 main protease non‐covalent and covalent inhibitors},
  journal = {Protein Science},
  year = {2023},
  doi = {10.1002/pro.4712}
}
Start for free →